Two Cases of Pilsicainide Intoxication showing the Brugada-type Electrocardiographic Findings and Incessant Wide QRS Tachycardia  by Sumiyoshi, Masataka et al.
Two Cases of Pilsicainide Intoxication showing
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We have experienced two patients with the Brugada-type electrocardiographic abnormal-
ities and incessant wide QRS tachycardia (presumed ventricular tachycardia) induced by
intoxication of a class IC antiarrhythmic drug pilsicainide. They were elderly men with
impaired renal function. Plasma concentration of pilsicainide was elevated to a toxic level in
both patients. After cessation of pilsicainide, incessant wide QRS tachycardia spontaneously
subsided and intraventricular conduction delay with coved type ST segment elevation in V1
and V2 disappeared. In the elderly or patients with renal dysfunction, we should be very
careful regarding dose adjustment of pilsicainide or it may be better to avoid using this drug.
(J Arrhythmia 2008; 24: 219–223)
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Pilsicainide, classiﬁed as a class IC drug, has a
strong sodium channel blocking eﬀect which de-
presses conduction in various regions of the heart.1)
Pilsicainide can unmask or aggravate the Brugada-
type electrocardiogram (ECG) in patients with latent
Brugada syndrome.2,3) We have experienced 2
patients with the Brugada-type ECG abnormalities
and incessant wide QRS tachycardia, presumed
ventricular tachycardia (VT), induced by intoxica-
tion of pilsicainide.
Case Presentation
Case 1: A 73-year-old man was referred to our
hospital for loss of consciousness. He had suﬀered
from hypertension and diabetes since he was 30-
year-old, and he had blood dialysis regularly in a
local clinic for chronic renal failure since he was 65.
He had been taking ﬂecainide (50mg per day) for 3
years because of paroxysmal atrial ﬁbrillation (AF).
However, two months ago, another clinic gave him
an additional prescription of pilsicainide 150mg per
day (50mg t.i.d.) for recurrent AF. On May 10,
2005, he had an episode of polymorphic wide QRS
tachycardia with loss of consciousness during he-
modialysis. The 12-lead ECG showed a regular wide
QRS rhythm of 80 beats/min without visible P
waves and marked coved-type ST segment elevation
in V1 and V2 (Figure 1, left). He was transferred
to our hospital to treat his presumed Brugada
syndrome. On admission, physical examination was
unremarkable. Chest X-ray revealed cardiomegaly
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Case Report
with a cardiothoracic ratio (CTR) of 57.5%, but no
signs of lung congestion. Laboratory examination
was remarkable for renal failure (BUN 40mg/dl and
serum creatine 11.4mg/dl) with normal electrolytes
(Na 139mEq/l and K 4.2mEq/l) and slight anemia
(Hb 10.8 g/dl). Echocardiographic examination
showed a mild dilatation of the left atrium and mild
to moderate hypertrophy of the left ventricle (LV)
with normal contraction; the ejection fraction was
70%. After admission, his ECG showed AF with
improvement of wide QRS complexes and ST
segment elevations; however, incessant monomor-
phic wide QRS tachycardia was observed (Figure 1,
right). Because of slow tachycardia with a rate of
95 to 100 beats/min, he was asymptomatic and his
systolic blood pressure was maintained at more than
100mmHg during the wide QRS tachycardia. We
suspected IC drug intoxication due to renal failure
from his medical history and ECG. Although the
plasma concentration of ﬂecainide was within the
normal range, that of pilsicainide was markedly
elevated to 4.52 mg/ml, which was 5 times more than
the therapeutic range (0.20–0.90 mg/ml). He was
treated with continuous saline infusion and hemo-
dialysis every other day. Incessant wide QRS
tachycardia spontaneously subsided after 2 days,
and intraventricular conduction delay and ST seg-
ment elevation in V1 and V2 disappeared as the
plasma concentration of pilsicainide decreased
(Figure 2). He was treated with digoxin and verapa-
mil for rate control and warfarin as an anticoagulant,
and discharged with persistent AF.
Case 2: A 77-year-old man was transferred to our
hospital for syncope. He had a history of thoracic
aortic aneurysm, which had been treated with a total
replacement of the aortic arch 2 years ago. He
suﬀered from incomplete paralysis in the lower
extremities due to spinal cord infarction after the
operation. He had been prescribed pilsicainide for
paroxysmal AF for more than 6 months. The dose of
pilsicainide was 50mg b.i.d. initially, but increased
to 100mg b.i.d. inadvertently 2 months before the
episodes of syncope. On admission, his physical
examination was unremarkable. The 12-lead ECG
showed no visible atrial activities and irregular QRS
complexes with incomplete right bundle branch
block pattern and coved-type ST segment elevation
in V1 and V2 (Figure 3, left). Before the admission,
incessant wide QRS tachycardia with a rate of about
120 beats/min was observed at the local clinic
(Figure 3, right). However, no wide QRS tachycardia
occurred after the admission, except for sporadic
ventricular premature beats. Chest X-ray showed
cardiomegaly with a CTR of 53.4% but no pulmo-
nary congestion. Laboratory examination showed
mild renal dysfunction (BUN 26.6mg/dl and the
serum creatinine 1.4mg/dl) with a normal potassium
level of 4.4mEq/l and slight anemia (Hb 10.4 g/dl).
Echocardiographic examination revealed normal LV
systolic function with an ejection fraction of 76%
and no hypertrophy or dilatation of LV. Left atrial
dimension was not dilated (29mm). We speculated
that it was due to pilsicainide intoxication from his
medical history and ECG ﬁndings, and examined
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Case 1
Figure 1 The ECGs in Case 1.
Left: A regular wide QRS rhythm of 80 beats/min without visible P waves and marked coved-type ST segment elevation in V1 and V2.
Right: Incessant monomorphic wide QRS tachyacardia with a rate of 95 to 100 beats/min observed after admission.
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the concentration of serum pilsicainide, which
indicated a toxic level of 4.09 mg/ml. After cessation
of pilsicainide, his ECG abnormalities, including
the coved-type ST elevation and intraventricular
conduction delay, disappeared in association with
decreased serum concentration of pilsicainide
(Figure 4). AF was converted to sinus rhythm sponta-
neously and did not recur during the hospitalization.
So we decided to follow up without antiarrhythmic
agents, but anticoagulation therapy with warfarin
was started. Then, he was transferred to another
hospital for rehabilitation of lower-extremity para-
lysis.
Discussion
Serious overdose of pilsicainide has been reported
to be characterized by severe bradycardia due to
sinus arrest or atrioventricular block, marked intra-
ventricular conduction delay, induction of VT, and
the Brugada-type ECG abnormalities.4–8) Our 2 cases
are unique because a typical Brugada-type ECG and
incessant wide QRS tachycardia occurred concom-
itantly due to pilsicainide intoxication; only one such
case had been reported earlier.7)
Pilsicainide is one of the drugs well known to
induce the Brugada-type ECG ﬁndings and is
commonly used for a provocation test, especially
in Japan, in order to ﬁnd a patient with latent
Brugada syndrome.2,3) Our 2 patients showed the
Brugada-type ECG ﬁndings temporarily due to
pilsicainide intoxication, and their ECG abnormal-
ities disappeared in association with reduction of
the plasma concentration of pilsicainide. Pilsicainide
intoxication is not always associated with the
Brugada-type ECG changes.4–6) It is not clear that
our patients have latent Brugada syndrome or
mutations of SCN5A because we did not perform
the genetic analysis. However, the most important
issue is whether they have similar clinical character-
istics or risk as those with Brugada syndrome. Priori
et al9) have reported that the patients who have a
diagnostic ECG only after provocation challenge by
the IC drug are at lower risk of cardiac events, and
the prognosis of asymptomatic patients without a
family history of SD is relatively good compared
with symptomatic patients. These ST-T changes may
be due to strong depression of intraventricular
conduction by pilsicainide intoxication. It is not
clear whether the ST-T changes due to intoxication
of IC drugs are caused by a similar mechanism as
Brugada syndrome. In addition, our patients only had
experienced syncope after administration of pilsicai-
nide. We made the assessment that our 2 patients
have a lower risk for future cardiac events and did
not perform further examinations or therapies except
for withdrawal of IC drugs.
We observed a wide QRS tachycardia in each
of our patients during acute phase; it disappeared
spontaneously in association with reduction of the
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Figure 2 Association between the ECG
ﬁndings and plasma concentration of pilsi-
cainede and ﬂecainide in Case 1.
Intraventricular conduction delay and ST seg-
ment elevation in V1 and V2 disappeared as the
plasma concentration of class IC drugs decreas-
ed. The therapeutic ranges of each drug are
shown in parentheses.
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plasma concentration of pilsicainide. The challenge
test with the administration of a class IC drug could
induce lethal ventricular arrhythmias.2,10) Incessant
and monomorphic VT is well known as a proar-
rhythmia induced by a strong slowing eﬀect of
intraventricular conduction due to class IC antiar-
rhythmic agents.11) Although we could not identify
their wide QRS tachyacardia as ventricular in origin,
we speculate that their incessant tachyacardia may
be VT as a proarrhythmic eﬀect due to intoxication
of IC drugs.
The plasma concentration of pilsicainide was
elevated to a toxic level (4 to 5 times over the upper
limit of the therapeutic range) in both patients, and
withdrawal of the drug eliminated the Brugada-type
ECG changes and incessant wide QRS tachyacardia.
Elderly patients can easily have a high concentration
of the drug due to latent renal failure or decreased
reserve in renal function. Although the dosage of
pilsicainide was within the usual doses, 150mg or
200mg per day in each patient, our patients were
elderly and their renal function was impaired:
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Figure 3 The ECGs in Case 2.
Left: Irregular QRS complexes with incomplete right bundle branch block pattern and coved-type ST segment elevation in V1 and V2.
Right: Incessant wide QRS tachycardia with a rate of about 120 beats/min observed in the local clinic.
Figure 4 Association between the ECG
ﬁndings and plasma concentration of pilsi-
cainede in Case 2.
ECG abnormalities, including the coved-type
ST elevation and intraventricular conduction
delay, disappeared correlated with the serum
concentration of pilsicainide. The therapeutic
range of pilsicainide is shown in parentheses.
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regular hemodialysis administered in case 1 and
serum creatinine was 1.5mg/dl in case 2. Plisicai-
nide is mainly excreted by the kidney12) and the
mean elimination rate by hemodialysis was 32%.13)
In addition, another IC drug ﬂecainide was concom-
itantly prescribed in case 1. In order to prevent
intoxication, we should be very careful regarding
dose adjustment of pilsicainide in the elderly or
patients with renal dysfunction, especially in patients
undergoing hemodialysis, and it may be better to
avoid using this drug in such patients.
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